HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Hangzhou Tongshifu Cultural and Creative Group - Potential for Future Growth Is Questionable

Pre-IPO Ganzhou Hemay Pharmaceutical - The Concerns on the Pipelines

Pre-IPO FS.COM - The Concerns Behind the Business Model and the Outlook

Equity Capital Markets

Yantai Lannacheng Biotechnology / Equity Capital Markets

<ul>
<li>The gap in nuclear medicine between China and international community is several decades. The reasons behind are complex and fatal. Lanacheng is a biotech with "high potential and high risk".</li>
<li>Various requirements pose extremely high challenges to commercialization in the nuclear medicine industry. The mature and complete upstream to downstream industrial chain of nuclear medicine itself has high barriers.</li>
<li>Investors need to recognize the risks of Lanacheng's products not being commercialized or the commercialization largely fall short of expectations, thus leading to continuous losses.Valuation would be lower than peer.</li>
</ul>


The gap in nuclear medicine between China and international community is several decades. The reasons behind are complex and fatal. Lanacheng is a biotech with "high potential and high risk".
Various requirements pose extremely high challenges to commercialization in the nuclear medicine industry. The mature and complete upstream to downstream industrial chain of nuclear medicine itself has high barriers.
Investors need to recognize the risks of Lanacheng's products not being commercialized or the commercialization largely fall short of expectations, thus leading to continuous losses.Valuation would be lower than peer.


Yantai Dongcheng Pharmaceuticl Gp (002675 CH)

Pre-IPO Yantai Lannacheng Biotechnology - There Is Still a Long Way to Go